The generic drug of metformin hydrochloride in the six plants passed the consistency evaluation

Metformin hydrochloride, which first was introduced in France in 1959, has the effect of controlling blood sugar in people with type 2 diabetesMetformin hydrochloride can reduce liver sugar production, inhibit glucose intestinal absorption, and increase the intake and utilization of glucose in peripheral tissues, which can increase the sensitivity of insulin by increasing the intake and use of peripheral sugaras of this announcement date, the drug six factory for the drug consistency evaluation has invested research and development costs of about 6.7 million yuan (unaudited), in 2018 the drug is not listed for salecurrently a total of 121 dimethyl hydrochloric acid tablets production approval, the main manufacturers in China are Shanghai Xinyi Balance Pharmaceutical Co., Ltd., Beijing Sihuan Pharmaceutical Co., Ltd., Guangdong South China Pharmaceutical Group Co., Ltdand Guizhou Tian'an Pharmaceutical Co., LtdAs of this announcement date, a total of 9 manufacturers, 10 product regulations through the State Drug Administration consistency evaluation and approvalAccording to minet data, the sales of metformin hydrochloride in 2018 were 340.9 million yuan in public hospitals, and retail sales in 22 key cities were 604.28 million yuan.